Is Single-Test Tuberculosis Screening Adequate Before Initiating Biologic Therapy?
Highlight
– Pretreatment screening with QuantiFERON-TB (QFT) Gold alone significantly reduced TB infection diagnoses and preventive therapy prescriptions compared to dual testing.
– Incident TB during biologic therapy remained low (0.8%), with most cases occurring within the first two years of treatment.
– Routine periodic TB retesting after a negative baseline screen appears unnecessary in the absence of new exposures.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.